IPO roundup: Sucampo prices low, Amedica’s IPO withdrawn
One deal down – Sucampo Pharmaceuticals, which had filed to raise as much as $69 million in its IPO (we covered them briefly here), priced its IPO well below expectations. Although the company had planned to sell shares for $14 to $16 apiece, it ended up pricing today at $11.50, a 23 percent discount. If the company still manages to over-allotted stock, it will fall just shy of raising $50 million. Sucampo shares, however, were up… Continue Reading
Amedica sets IPO terms, looks to raise $80.2M for implants
Amedica, a Salt Lake City device maker focused on spine, knee and hip implants, set its IPO terms and now hopes to raise as much as $80.2 million. The company plans to sell up to 5.3 million shares at a price of $13 to $15 apiece.
You can find our previous coverage of Amedica here and here. The company is notable in part because it listed the threat of government healthcare reform as a “risk factor”… Continue Reading
Implant maker Amedica files for $75M IPO
Salt Lake City-based Amedica filed to raise up to $74.8 million in an IPO, just a week after it raised $13.2 million in a fourth funding round. The maker of ceramic implants for spinal and joint repair said it doesn’t expect its first products to reach the market until next year.
Amedica’s S-1 filing, by the way, is the first I can recall seeing that explicitly lists “healthcare reform” as one of its major risk factors:
We… Continue Reading
Amedica raises $13.2M for spine and joint implants
Amedica, a Salt Lake City maker of ceramic implants for spines and joints, raised $13.2 million in a fourth round of funding. Creation Capital placed the financing. The company had previously raised more than $30 million.
The company is developing a line of ceramic knee, hip and spinal-disk replacements, along with related ceramic spine implants. Its release is here.